VRNA insider transactions
Verona Pharma plc (VRNA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for VRNA
- General Counsel Fisher Andrew returned 1,349,887 units of Ordinary Shares to the company and converted options into 931,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David returned 15,461,424 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. returned 3,564,852 units of Ordinary Shares to the company and converted options into 1,131,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W returned 14,550,248 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Austwick Michael returned 84,712 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ullman Anders returned 430,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Shah Mahendra returned 165,472 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Sinha Vikas returned 166,112 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Deschamps Lisa returned 156,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ebsworth David R returned 1,570,099 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Edwards Martin returned 229,992 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Brady James Aloysius returned 95,176 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Cunningham Kenneth returned 151,776 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ackermann Christina returned 136,072 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David gifted 1,200,000 units of Ordinary Shares, decreasing direct ownership by 9% to 12,176,144 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. gifted 189,600 units of Ordinary Shares, decreasing direct ownership by 7% to 2,417,872 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W gifted 1,200,000 units of Ordinary Shares, decreasing direct ownership by 10% to 11,264,968 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Cunningham Kenneth converted options into 24,000 units of Ordinary Shares and sold $142,057 worth of Ordinary Shares (10,808 units at $13.14), increasing direct ownership by 20% to 79,776 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Deschamps Lisa converted options into 24,000 units of Ordinary Shares and sold $124,392 worth of Ordinary Shares (9,464 units at $13.14), increasing direct ownership by 21% to 84,856 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- General Counsel Fisher Andrew converted options into 20,888 units of Ordinary Shares and sold $125,969 worth of Ordinary Shares (9,584 units at $13.14), increasing direct ownership by 3% to 417,903 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W sold $2,745,877 worth of Ordinary Shares (208,912 units at $13.14) and converted options into 255,696 units of Ordinary Shares, increasing direct ownership by 0.38% to 12,464,968 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. converted options into 70,888 units of Ordinary Shares and sold $766,751 worth of Ordinary Shares (58,336 units at $13.14), increasing direct ownership by 0.48% to 2,607,472 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ackermann Christina converted options into 24,000 units of Ordinary Shares and sold $23,764 worth of Ordinary Shares (1,808 units at $13.14), increasing direct ownership by 53% to 64,072 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Austwick Michael converted options into 24,000 units of Ordinary Shares and sold $148,366 worth of Ordinary Shares (11,288 units at $13.14) (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Brady James Aloysius converted options into 24,000 units of Ordinary Shares and sold $10,830 worth of Ordinary Shares (824 units at $13.14) (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David sold $2,745,877 worth of Ordinary Shares (208,912 units at $13.14) and converted options into 255,696 units of Ordinary Shares, increasing direct ownership by 0.35% to 13,376,144 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ebsworth David R converted options into 24,000 units of Ordinary Shares and sold $25,026 worth of Ordinary Shares (1,904 units at $13.14), increasing direct ownership by 3% to 880,499 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Edwards Martin converted options into 24,000 units of Ordinary Shares and sold $142,057 worth of Ordinary Shares (10,808 units at $13.14), increasing direct ownership by 9% to 157,992 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Shah Mahendra converted options into 24,000 units of Ordinary Shares and sold $47,422 worth of Ordinary Shares (3,608 units at $13.14), increasing direct ownership by 28% to 93,472 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Sinha Vikas converted options into 24,000 units of Ordinary Shares and sold $56,886 worth of Ordinary Shares (4,328 units at $13.14), increasing direct ownership by 26% to 94,112 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ullman Anders converted options into 24,000 units of Ordinary Shares, increasing direct ownership by 7% to 358,856 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W converted options into 229,512 units of Ordinary Shares and covered exercise/tax liability with 90,320 units of Ordinary Shares, increasing direct ownership by 1% to 12,418,184 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. converted options into 86,064 units of Ordinary Shares and covered exercise/tax liability with 37,616 units of Ordinary Shares, increasing direct ownership by 2% to 2,594,920 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- General Counsel Fisher Andrew converted options into 86,064 units of Ordinary Shares and covered exercise/tax liability with 39,464 units of Ordinary Shares, increasing direct ownership by 13% to 406,599 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David converted options into 229,512 units of Ordinary Shares and covered exercise/tax liability with 90,320 units of Ordinary Shares, increasing direct ownership by 1% to 13,329,360 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- General Counsel Fisher Andrew exercised 80,000 units of Ordinary Shares at a strike of $2.01 and sold $922,000 worth of Ordinary Shares (80,000 units at $11.53) (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Amendment: General Counsel Fisher Andrew exercised 80,000 units of Ordinary Shares at a strike of $2.01, increasing direct ownership by 22% to 439,999 units (SEC Form 4)4/A - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W sold $4,560,360 worth of Ordinary Shares (400,000 units at $11.40), decreasing direct ownership by 3% to 12,278,992 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David sold $4,560,520 worth of Ordinary Shares (400,000 units at $11.40), decreasing direct ownership by 3% to 13,190,168 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W sold $3,733,944 worth of Ordinary Shares (400,000 units at $9.33), decreasing direct ownership by 3% to 12,678,992 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David sold $3,734,579 worth of Ordinary Shares (400,000 units at $9.34), decreasing direct ownership by 3% to 13,590,168 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Sinha Vikas exercised 160,000 units of Ordinary Shares at a strike of $0.50 and sold $1,502,928 worth of Ordinary Shares (160,000 units at $9.39) (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Amendment: Director Sinha Vikas exercised 160,000 units of Ordinary Shares at a strike of $1.40 and sold $1,427,328 worth of Ordinary Shares (160,000 units at $8.92) (SEC Form 4)4/A - Verona Pharma plc (0001657312) (Issuer)
- General Counsel Fisher Andrew sold $685,600 worth of Ordinary Shares (80,000 units at $8.57) and exercised 80,000 units of Ordinary Shares at a strike of $2.11 (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ackermann Christina exercised 40,000 units of Ordinary Shares at a strike of $1.93 and sold $337,600 worth of Ordinary Shares (40,000 units at $8.44) (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. sold $1,014,343 worth of Ordinary Shares (114,984 units at $8.82), decreasing direct ownership by 4% to 2,546,472 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. sold $440,350 worth of Ordinary Shares (49,200 units at $8.95) and converted options into 50,000 units of Ordinary Shares, increasing direct ownership by 0.03% to 2,661,456 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W sold $5,311,479 worth of Ordinary Shares (587,008 units at $9.05) and converted options into 200,000 units of Ordinary Shares, decreasing direct ownership by 3% to 13,078,992 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Ebsworth David R exercised 140,000 units of Ordinary Shares at a strike of $1.93, increasing direct ownership by 10% to 1,476,003 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David sold $5,311,279 worth of Ordinary Shares (587,008 units at $9.05) and converted options into 200,000 units of Ordinary Shares, decreasing direct ownership by 3% to 13,990,168 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- General Counsel Fisher Andrew sold $234,127 worth of Ordinary Shares (26,072 units at $8.98), received a gift of 1 units of Ordinary Shares and converted options into 86,064 units of Ordinary Shares, increasing direct ownership by 20% to 359,993 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- President and CEO Zaccardelli David converted options into 229,512 units of Ordinary Shares and sold $811,433 worth of Ordinary Shares (90,360 units at $8.98), increasing direct ownership by 0.98% to 14,377,176 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Medical Officer Rickard Kathleen A. converted options into 86,064 units of Ordinary Shares and sold $308,768 worth of Ordinary Shares (34,384 units at $8.98), increasing direct ownership by 2% to 2,660,656 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Chief Financial Officer Hahn Mark W sold $811,433 worth of Ordinary Shares (90,360 units at $8.98) and converted options into 229,512 units of Ordinary Shares, increasing direct ownership by 1% to 13,466,000 units (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- Director Sinha Vikas exercised 20,000 units of Ordinary Shares at a strike of $1.40 and sold $178,416 worth of Ordinary Shares (20,000 units at $8.92) (SEC Form 4)4 - Verona Pharma plc (0001657312) (Issuer)
- SEC Form 4 filed by Director Ebsworth David R4 - Verona Pharma plc (0001657312) (Issuer)
- SEC Form 4 filed by Director Ullman Anders4 - Verona Pharma plc (0001657312) (Issuer)
- SEC Form 4 filed by Director Sinha Vikas4 - Verona Pharma plc (0001657312) (Issuer)
- SEC Form 4 filed by Director Shah Mahendra4 - Verona Pharma plc (0001657312) (Issuer)
- SEC Form 4 filed by Director Edwards Martin4 - Verona Pharma plc (0001657312) (Issuer)